Galderma Laboratories Patent-Cliff Exposure & CMS Drug Spending Portfolio
Galderma Laboratories (Fort Worth, TX): 8 reconciled FDA prescription therapies (51.0% 2025 to 2030 cliff risk), $6.6M 2024 CMS Part D & Medicaid spend, and $4,240 CA SB 17 specialty launch WAC.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Headquarters / Cluster | Fort Worth, TX |
| Reconciled FDA Portfolio Therapies | 8 |
| 2025 to 2030 Patent-Cliff Revenue Exposure | 51.0% |
| Primary Portfolio LOE Date | 2027-01-01 |
| 2024 CMS Total Public Spend | $6.6M |
| 2024 Medicare Part D Spend | $6.4M |
| 2024 Medicaid Spend | $162K |
| California HCAI SB 17 Filings | Specialty launch notice ($4,240 intro WAC) |